Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
51
FHTX Quote, Financials, Valuation and Earnings
Last price:
$5.35
Seasonality move
:
-23.21%
Day range:
$5.25 - $5.54
52-week range:
$2.94 - $6.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.46x
P/B ratio:
--
Volume:
73.4K
Avg. volume:
191K
1-year change:
7.57%
Market cap:
$305.4M
Revenue:
$22.6M
EPS (TTM):
-$1.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FHTX
Foghorn Therapeutics, Inc.
|
$6.2M | -$0.30 | 232.63% | -23.03% | $11.67 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
ERAS
Erasca, Inc.
|
-- | -$0.11 | -- | -4.86% | $5.13 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
OABI
OmniAb, Inc.
|
$5.6M | -$0.14 | -16.67% | -29.83% | $7.33 |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$19.4M | -$0.38 | 440.82% | -39.26% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FHTX
Foghorn Therapeutics, Inc.
|
$5.40 | $11.67 | $305.4M | -- | $0.00 | 0% | 13.46x |
|
CVM
CEL-SCI Corp.
|
$4.68 | $42.50 | $14.2M | -- | $0.00 | 0% | -- |
|
ERAS
Erasca, Inc.
|
$3.43 | $5.13 | $973.1M | -- | $0.00 | 0% | -- |
|
GTBP
GT Biopharma, Inc.
|
$0.85 | $8.00 | $9M | -- | $0.00 | 0% | 59.35x |
|
OABI
OmniAb, Inc.
|
$1.96 | $7.33 | $282.2M | -- | $0.00 | 0% | 10.02x |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$4.40 | $7.00 | $2.3B | -- | $0.00 | 0% | 40.36x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FHTX
Foghorn Therapeutics, Inc.
|
-33.56% | 2.098 | 8.15% | 2.13x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
ERAS
Erasca, Inc.
|
12.19% | 0.836 | 7.81% | 10.04x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
OABI
OmniAb, Inc.
|
7.06% | 2.112 | 9.15% | 4.71x |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
7.29% | 1.657 | 3.43% | 4.27x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FHTX
Foghorn Therapeutics, Inc.
|
$7.3M | -$18.5M | -- | -- | -226.92% | -$18.9M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
ERAS
Erasca, Inc.
|
-$755K | -$32.5M | -28.42% | -32.03% | -- | -$21.7M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
OABI
OmniAb, Inc.
|
-$2.4M | -$18.2M | -21.16% | -22.86% | -811.26% | -$9.9M |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
-$22.9M | -$172.2M | -72.69% | -80.23% | -3327.58% | -$117.6M |
Foghorn Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns FHTX or CVM?
CEL-SCI Corp. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of --. Foghorn Therapeutics, Inc.'s return on equity of -- beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital FHTXFoghorn Therapeutics, Inc.88.96% -$0.25 -$67.1M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About FHTX or CVM?
Foghorn Therapeutics, Inc. has a consensus price target of $11.67, signalling upside risk potential of 116.05%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 808.12%. Given that CEL-SCI Corp. has higher upside potential than Foghorn Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Foghorn Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FHTXFoghorn Therapeutics, Inc.9 0 0 CVMCEL-SCI Corp.1 0 0 -
Is FHTX or CVM More Risky?
Foghorn Therapeutics, Inc. has a beta of 3.043, which suggesting that the stock is 204.304% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock FHTX or CVM?
Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FHTX or CVM?
Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are larger than CEL-SCI Corp. quarterly revenues of --. Foghorn Therapeutics, Inc.'s net income of -$15.8M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 13.46x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FHTXFoghorn Therapeutics, Inc.13.46x -- $8.2M -$15.8M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns FHTX or ERAS?
Erasca, Inc. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of --. Foghorn Therapeutics, Inc.'s return on equity of -- beat Erasca, Inc.'s return on equity of -32.03%.
Company Gross Margin Earnings Per Share Invested Capital FHTXFoghorn Therapeutics, Inc.88.96% -$0.25 -$67.1M ERASErasca, Inc.-- -$0.11 $396.2M -
What do Analysts Say About FHTX or ERAS?
Foghorn Therapeutics, Inc. has a consensus price target of $11.67, signalling upside risk potential of 116.05%. On the other hand Erasca, Inc. has an analysts' consensus of $5.13 which suggests that it could grow by 49.42%. Given that Foghorn Therapeutics, Inc. has higher upside potential than Erasca, Inc., analysts believe Foghorn Therapeutics, Inc. is more attractive than Erasca, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FHTXFoghorn Therapeutics, Inc.9 0 0 ERASErasca, Inc.6 1 0 -
Is FHTX or ERAS More Risky?
Foghorn Therapeutics, Inc. has a beta of 3.043, which suggesting that the stock is 204.304% more volatile than S&P 500. In comparison Erasca, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock FHTX or ERAS?
Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Erasca, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. Erasca, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FHTX or ERAS?
Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are larger than Erasca, Inc. quarterly revenues of --. Foghorn Therapeutics, Inc.'s net income of -$15.8M is higher than Erasca, Inc.'s net income of -$30.6M. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while Erasca, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 13.46x versus -- for Erasca, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FHTXFoghorn Therapeutics, Inc.13.46x -- $8.2M -$15.8M ERASErasca, Inc.-- -- -- -$30.6M
-
Which has Higher Returns FHTX or GTBP?
GT Biopharma, Inc. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of --. Foghorn Therapeutics, Inc.'s return on equity of -- beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital FHTXFoghorn Therapeutics, Inc.88.96% -$0.25 -$67.1M GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About FHTX or GTBP?
Foghorn Therapeutics, Inc. has a consensus price target of $11.67, signalling upside risk potential of 116.05%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 846.75%. Given that GT Biopharma, Inc. has higher upside potential than Foghorn Therapeutics, Inc., analysts believe GT Biopharma, Inc. is more attractive than Foghorn Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FHTXFoghorn Therapeutics, Inc.9 0 0 GTBPGT Biopharma, Inc.1 0 0 -
Is FHTX or GTBP More Risky?
Foghorn Therapeutics, Inc. has a beta of 3.043, which suggesting that the stock is 204.304% more volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock FHTX or GTBP?
Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FHTX or GTBP?
Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are larger than GT Biopharma, Inc. quarterly revenues of --. Foghorn Therapeutics, Inc.'s net income of -$15.8M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 13.46x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FHTXFoghorn Therapeutics, Inc.13.46x -- $8.2M -$15.8M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns FHTX or OABI?
OmniAb, Inc. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of -738.05%. Foghorn Therapeutics, Inc.'s return on equity of -- beat OmniAb, Inc.'s return on equity of -22.86%.
Company Gross Margin Earnings Per Share Invested Capital FHTXFoghorn Therapeutics, Inc.88.96% -$0.25 -$67.1M OABIOmniAb, Inc.-109.2% -$0.14 $298.5M -
What do Analysts Say About FHTX or OABI?
Foghorn Therapeutics, Inc. has a consensus price target of $11.67, signalling upside risk potential of 116.05%. On the other hand OmniAb, Inc. has an analysts' consensus of $7.33 which suggests that it could grow by 274.15%. Given that OmniAb, Inc. has higher upside potential than Foghorn Therapeutics, Inc., analysts believe OmniAb, Inc. is more attractive than Foghorn Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FHTXFoghorn Therapeutics, Inc.9 0 0 OABIOmniAb, Inc.7 0 0 -
Is FHTX or OABI More Risky?
Foghorn Therapeutics, Inc. has a beta of 3.043, which suggesting that the stock is 204.304% more volatile than S&P 500. In comparison OmniAb, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock FHTX or OABI?
Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OmniAb, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. OmniAb, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FHTX or OABI?
Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are larger than OmniAb, Inc. quarterly revenues of $2.2M. Foghorn Therapeutics, Inc.'s net income of -$15.8M is higher than OmniAb, Inc.'s net income of -$16.5M. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while OmniAb, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 13.46x versus 10.02x for OmniAb, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FHTXFoghorn Therapeutics, Inc.13.46x -- $8.2M -$15.8M OABIOmniAb, Inc.10.02x -- $2.2M -$16.5M
-
Which has Higher Returns FHTX or RXRX?
Recursion Pharmaceuticals, Inc. has a net margin of -194.4% compared to Foghorn Therapeutics, Inc.'s net margin of -3135.32%. Foghorn Therapeutics, Inc.'s return on equity of -- beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.
Company Gross Margin Earnings Per Share Invested Capital FHTXFoghorn Therapeutics, Inc.88.96% -$0.25 -$67.1M RXRXRecursion Pharmaceuticals, Inc.-442.74% -$0.36 $1.1B -
What do Analysts Say About FHTX or RXRX?
Foghorn Therapeutics, Inc. has a consensus price target of $11.67, signalling upside risk potential of 116.05%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 59.09%. Given that Foghorn Therapeutics, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Foghorn Therapeutics, Inc. is more attractive than Recursion Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FHTXFoghorn Therapeutics, Inc.9 0 0 RXRXRecursion Pharmaceuticals, Inc.1 5 0 -
Is FHTX or RXRX More Risky?
Foghorn Therapeutics, Inc. has a beta of 3.043, which suggesting that the stock is 204.304% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock FHTX or RXRX?
Foghorn Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Foghorn Therapeutics, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FHTX or RXRX?
Foghorn Therapeutics, Inc. quarterly revenues are $8.2M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Foghorn Therapeutics, Inc.'s net income of -$15.8M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Foghorn Therapeutics, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Foghorn Therapeutics, Inc. is 13.46x versus 40.36x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FHTXFoghorn Therapeutics, Inc.13.46x -- $8.2M -$15.8M RXRXRecursion Pharmaceuticals, Inc.40.36x -- $5.2M -$162.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 0.32% over the past day.
Buy
64
ZCSH alert for Dec 26
Grayscale Zcash Trust (ZEC) [ZCSH] is down 1.79% over the past day.
Buy
66
ASTS alert for Dec 26
AST Spacemobile, Inc. [ASTS] is down 6.09% over the past day.
